Hemophilia A, Severe
Showing 1 - 25 of >10,000
Reliability and Validity of the Turkish Version of the PedHAL
Not yet recruiting
- Hemophilia
- +2 more
-
Gaziantep, Şahinbey, TurkeyHasan Kalyoncu University
Jun 2, 2023
Hemophilia B Without Inhibitor Trial (Low dose KL001, Middle dose KL001, High dose KL001)
Not yet recruiting
- Hemophilia B Without Inhibitor
- Low dose KL001
- +2 more
- (no location specified)
Nov 5, 2023
Hemophilia B Without Inhibitor Trial (Low dose KL001, Middle dose KL001, High dose KL001)
Not yet recruiting
- Hemophilia B Without Inhibitor
- Low dose KL001
- +2 more
- (no location specified)
Nov 5, 2023
Severe Hemophilia A Without Inhibitor, Joint Bleed Trial in Bangkok ("Emicizumab", "HEMLIBRA®")
Recruiting
- Severe Hemophilia A Without Inhibitor
- Joint Bleed
- "Emicizumab", "HEMLIBRA®"
-
Bangkok, ThailandKing Chulalongkorn Memorial hospital
Nov 25, 2023
Bleeding Rates Among Severe Hemophilia A on Emicizumab
Not yet recruiting
- Hemophilia A
-
Newark, New JerseyNewark Beth Israel Medical Center
Oct 26, 2023
Dynamics of Anti-factor VIII Antibody Signature During Treatment
Not yet recruiting
- Severe Hemophilia A
- +2 more
- no interventions
- (no location specified)
Apr 4, 2023
Hemophilia B Trial (CSL222 (AAV5-hFIXco-Padua))
Not yet recruiting
- Hemophilia B
- CSL222 (AAV5-hFIXco-Padua)
- (no location specified)
Aug 14, 2023
Hemophilia A Trial in Roma (SenseWear armband device)
Completed
- Hemophilia A
- SenseWear armband device
-
Roma, ItalyFPG
Mar 1, 2023
Hemophilia A Trial in Little Rock (ASC618)
Recruiting
- Hemophilia A
- ASC618
-
Little Rock, ArkansasArkansas Children's Hospital
Jan 30, 2023
Hemophilia A Trial (Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin
Not yet recruiting
- Hemophilia A
- Fitusiran (SAR439774)
- +3 more
- (no location specified)
Nov 17, 2023
Hemophilia A Trial in Abidjan (Prophylaxis with Emicizumab)
Completed
- Hemophilia A
- Prophylaxis with Emicizumab
-
Abidjan, Côte D'IvoireCHU de Yopougon
Oct 24, 2022
Hemophilia A, Hemophilia B Trial in Korea, Republic of, South Africa, Taiwan (marstacimab)
Recruiting
- Hemophilia A
- Hemophilia B
-
Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
- +3 more
Jan 18, 2023
Hemophilia B Trial in Beijing (Sodium valproate extended-release tablets)
Recruiting
- Hemophilia B
- Sodium valproate extended-release tablets
-
Beijing, ChinaPLA General Hospital
Jun 17, 2023
Severe Hemophilia A Subjects Who Received BMN 270 inPrior
Enrolling by invitation
- Hemophilia A
-
London, United KingdomRoyal London Hospital, Barts and the London Hemophilia Center
Mar 13, 2023
A Prospective and Retrospective Interventional Study on
Recruiting
- Severe Hemophilia A Without Inhibitor
- serum biomarker.
-
Taipei, Neihu Dist., TaiwanTri-Service General Hospital Hemophilia Care Center
Aug 10, 2023
Hemophilia Trial in Bangkok (combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided
Completed
- Hemophilia
- combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
- pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
-
Bangkok, ThailandKing Chulalongkorn Memorial Hospital
Feb 5, 2023
Severe Hemophilia Non-Interventional Study
Not yet recruiting
- Hemophilia A
- Hemophilia B
- No Intervention
-
Rzeszów, Podkarpackie, Poland
- +2 more
Dec 8, 2022
Hemophilia Trial in Orange (Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate
Recruiting
- Hemophilia
- Fitusiran
- +2 more
-
Orange, CaliforniaCenter for Inherited Blood Disorders (CIBD)-Site Number:8400012
Feb 2, 2023
Hemophilia Trial (BFRT, Control)
Not yet recruiting
- Hemophilia
- BFRT
- Control
- (no location specified)
Dec 14, 2022
Emicizumab on Activated Clotting Time Using i-STAT Alinity
Not yet recruiting
- Hemophilia A
- ACT
- (no location specified)
May 9, 2023